TheraVet SA (ALVET.PA)
EUR 0.11
(-0.46%)
EUR 0.11
(-0.46%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.07 Million EUR | -92.64% |
| 2022 | 1.6 Million EUR | -17.54% |
| 2021 | 1.94 Million EUR | 96.65% |
| 2020 | 987.8 Thousand EUR | 26.54% |
| 2019 | 780.64 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 225.2 Thousand EUR | 0.0% |
| 2024 Q1 | 225.2 Thousand EUR | -3.74% |
| 2023 Q2 | 55.26 Thousand EUR | -81.88% |
| 2023 Q1 | 305.07 Thousand EUR | 494.88% |
| 2023 Q4 | 233.95 Thousand EUR | 0.0% |
| 2023 Q3 | 233.95 Thousand EUR | 323.32% |
| 2023 FY | 117.83 Thousand EUR | -92.64% |
| 2022 Q1 | 456.39 Thousand EUR | 4286.34% |
| 2022 Q3 | 344.49 Thousand EUR | 705.77% |
| 2022 Q4 | 51.28 Thousand EUR | -85.11% |
| 2022 FY | 1.6 Million EUR | -17.54% |
| 2022 Q2 | 42.75 Thousand EUR | -90.63% |
| 2021 Q1 | 457.87 Thousand EUR | 29.38% |
| 2021 Q3 | 513.41 Thousand EUR | 26323.57% |
| 2021 Q2 | 1943.00 EUR | -99.58% |
| 2021 FY | 1.94 Million EUR | 96.65% |
| 2021 Q4 | 10.4 Thousand EUR | -97.97% |
| 2020 Q4 | 353.9 Thousand EUR | 0.0% |
| 2020 Q3 | 353.9 Thousand EUR | 152.79% |
| 2020 Q2 | 140 Thousand EUR | 0.0% |
| 2020 FY | 987.8 Thousand EUR | 26.54% |
| 2020 Q1 | 140 Thousand EUR | 0.0% |
| 2019 FY | 780.64 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 76.766% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 76.671% |
| Adocia SA | 2.15 Million EUR | 49.858% |
| Aelis Farma SA | 9.05 Million EUR | 88.093% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 65.787% |
| genOway Société anonyme | 20.04 Million EUR | 94.622% |
| IntegraGen SA | 12.53 Million EUR | 91.401% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -259.311% |
| Neovacs S.A. | 533.41 Thousand EUR | -102.106% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | 35.888% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -5345.822% |
| Sensorion SA | 4.74 Million EUR | 77.271% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -263.801% |
| TME Pharma N.V. | 17 Thousand EUR | -6241.5% |
| Valbiotis SA | 4.73 Million EUR | 77.223% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | 40.108% |
| argenx SE | 1.13 Billion EUR | 99.905% |
| BioSenic S.A. | 543 Thousand EUR | -98.537% |
| Celyad Oncology SA | 102 Thousand EUR | -956.917% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.55% |
| Genfit S.A. | 28.56 Million EUR | 96.226% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | 48.344% |
| Innate Pharma S.A. | 51.9 Million EUR | 97.923% |
| Inventiva S.A. | 17.47 Million EUR | 93.832% |
| MaaT Pharma SA | 2.22 Million EUR | 51.613% |
| MedinCell S.A. | 9.16 Million EUR | 88.231% |
| Nanobiotix S.A. | 30.05 Million EUR | 96.413% |
| Onward Medical N.V. | 532 Thousand EUR | -102.642% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 92.404% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 51.592% |
| Oxurion NV | 263 Thousand EUR | -309.907% |
| Pharming Group N.V. | 245.31 Million EUR | 99.561% |
| Poxel S.A. | 1.98 Million EUR | 45.58% |
| GenSight Biologics S.A. | 1.26 Million EUR | 14.913% |
| Transgene SA | 1.18 Million EUR | 8.948% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.979% |
| Valneva SE | 153.71 Million EUR | 99.299% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 129.781% |